Perugia, Italy

Nicola Giacche

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Tes Pharma S.r.l.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nicola Giacche: Innovator in Pharmaceutical Compounds

Introduction

Nicola Giacche is a notable inventor based in Perugia, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate specific enzymatic activities. His work is crucial for addressing various health issues related to metabolic and neurodegenerative disorders.

Latest Patents

Nicola Giacche holds a patent for "Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase." This patent discloses compounds capable of modulating the activity of α-amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD). These compounds are useful for the prevention and treatment of diseases associated with defects in NAD biosynthesis, including metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and age-related diseases. The patent also includes pharmaceutical compositions comprising these compounds and their use as medicaments.

Career Highlights

Nicola Giacche is associated with Tes Pharma S.r.l., where he continues to innovate in the pharmaceutical sector. His work has the potential to impact the treatment of various diseases significantly.

Collaborations

Some of his notable coworkers include Roberto Pellicciari and Paride Liscio, who contribute to the collaborative efforts in research and development at Tes Pharma S.r.l.

Conclusion

Nicola Giacche's innovative work in developing pharmaceutical compounds showcases his commitment to advancing medical science. His contributions are vital for addressing complex health challenges, and his patent reflects the potential for significant therapeutic advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…